Editor’s Note: Former hedge fund manager Larry Benedict believes Nvidia’s earnings on Wednesday could open a narrow window for an unusual new trade. He’ll reveal the ticker live just hours later. Attend the briefing, and Larry will send you his next trade recommendation on that ticker completely free, as soon as it’s ready. Details below…
In 2022, my members had the opportunity to book 14 winning trades in a row.
Inside that run, one six-trade sequence created the potential to turn $10,000 into more than $156,000…
Those trades came during the same market turmoil that forced 40% of workers over 45 to delay retirement by an average of four years.
Most people were blindsided.
But for anyone prepared to trade what was happening, it created one opportunity after another.
Now, I believe the market is setting up to do it again.
And Nvidia’s earnings on Wednesday could open the window.
The trade I’m lining up is not Nvidia.
It isn’t another AI stock.
It’s something entirely different…
It’s one overlooked ticker sitting directly in the path of as much as $22 trillion flooding through the markets.
Almost nobody is watching this ticker today.
But that could change very quickly after Nvidia reports.
That’s why I’m holding The AI Retirement Reset Emergency Briefing.
Show you why the next few weeks could produce a rapid succession of new
And explain why I believe it’s critical you act before September 16.
Better still, attend the briefing, and I’ll send you the next trade I recommend making on this ticker, completely free, as soon as the opportunity is available.
The briefing begins Wednesday, August 26, at 8 p.m. ET.
(Clicking the link above will opt you into emails from The Opportunistic Trader and Brownstone Research, including the Trading with Larry Benedict daily E-letter. You can unsubscribe at any time. Please view our Privacy Policy for more details.)
Founder, The Opportunistic Trader
(Clicking the link above will opt you into emails from The Opportunistic Trader and Brownstone Research, including the Trading with Larry Benedict daily E-letter. You can unsubscribe at any time. Please view our Privacy Policy for more details.
Market Signal Report
Merck printed the melanoma readout. WMT is Thursday morning.
MARKET SIGNAL REPORT
POWERED BY STOCKSTOTRADE
|
|
WEDNESDAY, AUGUST 19, 2026
S&P ▲0.38% Nasdaq ▲0.01% Dow ▲0.31% Yields / buybacks
|
|
Moderna is $154.24, up 145%, on 138 million shares. Merck and Moderna said Phase 3 INTerpath-001 met recurrence-free and distant metastasis-free survival in resected stage IIB-IV melanoma. First positive Phase 3 for an individualized mRNA cancer therapy. The PR hit at 6:45 a.m. ET. SPY is 770.38, up 0.38%. QQQ is 717.58, up 0.01%. DIA is 534.55, up 0.31%. IWM is 301.92, up 0.56%. Yields eased after Treasury said it would at least double 10-year and 30-year buybacks. CNBC had the 10-year near 4.65%, down 5 bp. These are afternoon prints around 1:02 p.m. CT, not the close.
The indexes are green on the buyback print. Target already reported this morning. That is not why the S&P is up. Underneath, it is an mRNA cluster plus two names that do not belong in the same sentence. TNON is a reverse-split leftover. 👇
|
|
📈 TODAY'S TOP 5 GAINERS
1 · MRNA
+145.0%
$154.24 on 138.4 million shares. Merck/Business Wire, 6:45 a.m. ET: Phase 3 INTerpath-001 met RFS and DMFS in resected stage IIB-IV melanoma. First positive P3 for an individualized mRNA cancer therapy.
|
2 · MRVI
+22.7%
$7.05 on 8.5 million shares. Nucleic-acid reagents on the same mRNA-cancer readout. Q2 last night; FY26 adjusted EBITDA raised to $33-35 million.
|
3 · BNTX
+20.4%
$111.66 on 6.6 million shares. Peer re-rate on a trial BNTX does not own. Leerink, via Seeking Alpha at 12:08 p.m. ET, said the rally is likely to fade.
|
4 · TWST
+17.6%
$136.49 on 2.3 million shares, a 52-week high. Anthropic's August 18 blog and 8-K named Twist a wet-lab evaluator for Claude protein binders. Different tape than the melanoma print.
|
5 · EL
+16.7%
$98.36 on 9.0 million shares. FY2026/Q4 beat, FY27 outlook, margins upgraded. Business Wire 6:00 a.m. ET. Cosmetics, not mRNA.
|
🎯 THE SIGNAL
MRNA is the session. The Phase 3 is dated, Merck is the partner, and the stock is already up 145% on the morning PR. That is not a buy-the-afternoon print. BNTX is a peer re-rate on a trial it does not own. MRVI is reagents on the same readout. MRK is +11.9% as the co-author and did not make the five. TWST is yesterday's Anthropic wet-lab mention. EL is a cosmetics beat. TNON is reverse-split noise. The leftover is the percent. The session is the morning trial.
|
|
|
Norway's $2 trillion fund chief just called this market abnormal. Meanwhile Riot locked 191 megawatts of data-center capacity to Anthropic in a 20-year, $9.1 billion deal. Alexander Green at The Oxford Club says the crowded Nvidia/Apple pile is the trap, and he found a publicly traded vehicle whose largest holding is Anthropic. Same backdoor idea as SpaceX, before the IPO scramble. Learn about the ticker before the trade gets crowded.
|
|
|
📊 THE HEADLINE THAT MATTERED
"Moderna, Merck Report Positive Phase 3 Trial Results of Melanoma Drug; Moderna Shares Jump Over 100%"
MT Newswire PRO Global via QuoteMedia, 1:39 p.m. ET, August 19, 2026. The primary PR is Merck/Business Wire at 6:45 a.m. ET.
The index tape is a different story. Yields eased on the Treasury buyback cap. Canada tariffs got a pause. Target's beat this morning is a retail print, not why SPY is green.
|
|
👀 ONE TO WATCH TOMORROW
🛒 Walmart
(WMT)
Q2 FY2027 Thursday. Materials around 6:00 a.m. CT. Live call at 7:00 a.m. CT.
Why it's the watch: Lowe's printed today and cut the year to the low end. Target printed this morning. Home Depot was Tuesday. WMT is the last big consumer read of the week.
The tell: U.S. comps and whether they hold the year after LOW already walked the outlook down. Let the 7 a.m. CT call print first.
|
See you at the next signal. 📡
Market Signal Report
powered by StocksToTrade
|
|
Signal over noise. Every trading day.
|
|